Fuente: Historias Clínicas.

Referencias bibliográficas.

1. Fitzpatrick’s.Dermatology in General Medicine. 6a e. N.Y McGraw-Hill Medical Publishing Division 2003; cap 73 672-687.
2. Urmila Bhor,Sushil Pande. Scorig system in Dermatology.Indian J. Dermatol Venerol Leprol. (72):315-21. 2006.
3. Kang WH; Yoon KH; Lee ES; Kim J; Lee KB; Yim H; Sohn S; Im S. Melasma: histopathological characteristics in 56 Korean patients. Br Dermatol; 146 (2):228-37, Feb 2002.
4. Torok HM; Jones T; Rich P; Smith S; Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis; 75 (1):57-62, Jan 2006.
5. Yuan-Hong Li MD, John Z.S. Chen MD, Hua-Chen Wei MD, Yan Wu MD, Mei Liu MD, Yuan-Yuan Xu MD, Guang-Hui Dong PHD, Hong-Duo Chen MD. Efficacy and Safety of Intense Pulsed Light in Treatment of Melasma in Chinese Patients Dermatologic Surgery 34 (5), 693–701 doi:10.1111/j.1524-4725. 34130, 2008.
6. REBAT M. HALDER & GEORGIANNA M. RICHARDS. Management of dyschromias in ethnic skin. Dermatologic Therapy, Vol. (17), 151–157 2004.
7. El -Essawi D; Musial JL; Hammad A; Lim HW. A survey of skin disease and skin-related issues in Arab Americans.: J Am cad Dermatol;56 (6):933-8 2007.
8. Pandya,* M. Berneburg,f J.-P. OrtonneJ and M. Picardos. Guidelines for clinical triáis in melasma.Journal of Dermatology, 156 (suppl1), 21–28, 2007.
9. Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish languageJ Am Acad Dermatol. Jul 2006; 55 (1):59-66.
10. Salim A, Rengifo M, Cuervo-Amore LG, Tweed J, Vincent S. Interventions for melasma In: The Cochrane Library, Issue 2007.
11. Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a sample of women living in sou thern Brazil. Br J Dermatol. Sep; 149 (3):572-7 2008. Consultado octubre 2009. Disponible en: en http:// www. ncbi.n lm.nih.g ov/pubmed/1 8410339?ordinal pos=1&itool=Entre zSystem2. PEntrez.Pu bmed.Pubm ed_Re sultsPan el.Pubme d_RVDocSum
12. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR, RêgoVR, Mendes AM, Filho JW, Junqueira H.Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy:BrJDermatol. Dec2006;156 Suppl 1:13-http://ww w.ncbi.nlm. nih.gov/pub med/17176300 ?ord inalpos=1&itool =EntrezSystem2 .PEntrez.Pubmed.Pub med_Re sultsPa nel.Pubmed_ Discove ryPane l.Pubmed_Discove ry_RA&linkpos=1 &log$=relatedartic les&dbfrom =pubmed 12 mayo 2008
13. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren MM. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol.Sep 2003; 149 (3):5727 http://www.n cbi.nlm.nih.g ov/pubmed/1 4510991?ordi nalpos=1&itoo l=EntrezSystem 2.PEntrez.Pubm ed.Pubmed_Re sultsPanel.Pub med_Discovery Panel.Pu bmed_Dis covery_RA&linkpos=2&log $=related articles&db from=p ubmed consultado 12 octubre 2009.
14. Kang WH; Yoon KH; Lee ES; Kim J; Lee KB; Yim H; Sohn S; Im S. Melasma: histopathological characteristics in 56 Korean patients. Br Dermatol; 146 (2):228-37, Feb 2002.
15. Kim EH; Kim YC; Lee ES; Kang HY.The vascular characteristics of melasma. J Dermatolo Sci; 46 (2): 111-6, May 2007.
16. Pérez MI. The stepwise approach to the treatment of melasma. Cutis; 75 (4):217-22, Apr 2005.
17. Gupta AK; Gover MD; Nouri K; Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol; 55 (6):1048-65, Dec 2006.
18. Picardo M, Carrera M. New and experimental treatments of cloasma and other hypermelanoses.Dermatol Clin. 2007 Jul; 25 (3):353-62, ix. Review.
19. Ferreira Cestari T; Hassun K; Sittart A; de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma:J Cosmet Dermatol;6 (1):36-9, Mar 2007. 1473-2165
20. Torok HM; Jones T; Rich P; Smith S; Tschen E. (2005): Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis; 75 (1):57-62, Jan 2006.
21. Erbil H; Sezer E; Tastan B; Arca E; Kurumlu Z. Efficacy and safety of serial glycolicacid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol; 34 (1):25-30, Jan 2007.
22. Kar HK. Efficacy of beta-carotene topical application in melasma: an open clinical trial. Indian J Dermatol Venereol Leprol. Nov-Dec 2002;68 (6):320-2
23. Park JH; Choi YD; Kim SW; Kim YC; Park SW. Effectiveness of modified phenol peel (Exoderm) on facial wrinkles, acne scars and other skin problems of Asian patients. J Dermatol; 34 (1):17-24, Jan 2007.
24. Scherdin U, Bürger A, Bielfeldt S, Filbry A, Weber T, Schölermann A, Wigger-Alberti W, Rippke F, Wilhelm KP. Skin-lightening effects of a new face care product in patients with melasma. J Cosmet Dermatol. Mar 2008; 7 (1):68-75 disponible en: http://www. ncbi. nlm.nih.gov/pu bmed/1825 481 5?ordin alpos= 24&itool=Ent rezSys tem2.P Entrez.Pubme d.Pubmed_Re sults qPanel.Pubm ed_RVD ocSum 12 mayo 2008.
25. Kurita M; Momosawa A; Ozaki M; Ban I; Harii K. Long-pulsed dye laser for the treatment of erythromelanosis follicularis faciei: report of two clinical cases. Dermatol Surg; 32 (11):1414-7, Nov 2006.
26. Pérez Jiménez AY I Congreso Nacional de Termalismo, 1999. Cuba. (l Centro de Convenciones de Cojímar).
27. Pérez Jiménez AY XXIX Congreso de la Sociedad Internacional de Técnicas Hidrotermales, 1993.Habana, Cuba (Palacio de las convenciones).
28. Pérez Jiménez AY II Jornada Nacional de Termalismo. 1994. Sancti Spíritus Cuba (Topes de Collantes).
29. NC: XX 1998: Norma Cubana. Peloides. Especificaciones. La Habana: Oficina Nacional de Normalización;
30. Pérez Jiménez Y. Rodríguez R. Iglesias M. Vega L. Resultados del uso de Peloides en el tratamiento de algunas afecciones dermatológicas. Rev. Cub. de Medicina Sep.-Dic. 1991;30 (3)
31. Rodríguez R.; Pérez Y; Iglesias, M; Vega L; Rodríguez A. Tratamiento de la enfermedad articular degenerativa con peloides: experiencia de 18 meses de trabajo MediCiego; 1:2-5 ene-mar 1995.
32. Pérez Jiménez AY. Acción de los fangos medicinales en el melasma MediCiego. 8 (1), enero-julio.2002.
33. Diaz A.; García A.; Veloso G.; Seara A. Peloides en el tratamiento de las afecciones dermatológicas. Archivo Médico de Camagüey 8 (1) 2004.
34. Pérez Jiménez AY. Uso de peloides en Dermatología. Cienfuegos. Taller Internacional de Dermatología; ISBM 259-0985 2006.
35. Pérez Jiménez AY. VI Congreso Internacional de Medicina Tradicional Natural y Bioenergética. Holguín Cuba 2008.